Source comparison
Thymosin Alpha-1 Hepatitis Results Timeline: Protocol Comparison
Tα1 Monotherapy (1.6mg 2×/week, 24 weeks) CD4/CD8 normalisation at 6–8 weeks; IL-2 increase at 8–10 weeks First measurable decline at 12–16 weeks; progressive reduction through week 24 28–35% (HBV), 30–42% (HCV genotype 1) Slowest viral clearance but lowest ad
This comparison does not assign a generated winner or score.
- Tα1 Monotherapy (1.6mg 2×/week, 24 weeks)
- CD4/CD8 normalisation at 6–8 weeks; IL-2 increase at 8–10 weeks
- First measurable decline at 12–16 weeks; progressive reduction through week 24
- 28–35% (HBV), 30–42% (HCV genotype 1)
- Slowest viral clearance but lowest adverse event rate; best for mild-moderate disease without cirrhosis
- Tα1 + Nucleoside Analogue (HBV)
- CD4/CD8 normalisation at 4–6 weeks; earlier cytokine response
- Viral load drops within 4–6 weeks (antiviral effect); immune contribution visible after week 10
- 58–64%
- Synergistic mechanism: antiviral suppresses replication while Tα1 rebuilds immune control; standard of care in most centres
- Tα1 + Direct-Acting Antiviral (HCV)
- Immune reconstitution at 6–8 weeks; sustained even post-DAA
- Rapid viral clearance (DAA effect dominant); Tα1 reduces relapse risk
- 62–71%
- Tα1 primarily reduces post-treatment relapse by enhancing memory T-cell response; used in genotype 3 and cirrhotic patients
- High-Dose Tα1 (3.2mg 2×/week, 48 weeks)
- Similar timeline to standard dose; slightly higher IL-2 peak
- Marginal acceleration (1–2 weeks earlier decline vs 1.6mg)
- 35–42% (monotherapy)
- Limited dose-response benefit above 1.6mg; higher cost without proportional efficacy gain